Do analysts rate TELO or PBYI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SOPH or TELO?

SOPHiA GENETICS presently has a consensus target price of $7.50, suggesting a potential upside of 43.40%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, research analysts plainly believe SOPHiA GENETICS is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate TELO or ENTA?

Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 44.28%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Do analysts prefer GLSI or TELO?

Greenwich LifeSciences presently has a consensus target price of $47.50, indicating a potential upside of 106.25%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, GLSI or TELO?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is GLSI or TELO more profitable?

Telomir Pharmaceuticals' return on equity of -201.23% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% Telomir Pharmaceuticals N/A -201.23% -172.71%

Do analysts rate STTK or TELO?

Shattuck Labs presently has a consensus target price of $11.00, indicating a potential upside of 104.08%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is STTK or TELO more profitable?

Shattuck Labs' return on equity of -60.73% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Telomir Pharmaceuticals N/A -201.23% -172.71%

Telomir Pharmaceuticals (TELO) Competitors

$1.25 -0.03 (-2.34%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.27 +0.02 (+2.00%)

As of 04:06 AM Eastern

Compare

TELO vs. PBYI, SOPH, ENTA, GLSI, and STTK

Should you buy Telomir Pharmaceuticals stock or one of its competitors? MarketBeat compares Telomir Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telomir Pharmaceuticals include Puma Biotechnology (PBYI), SOPHiA GENETICS (SOPH), Enanta Pharmaceuticals (ENTA), Greenwich LifeSciences (GLSI), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry.

How does Telomir Pharmaceuticals compare to Puma Biotechnology?

Telomir Pharmaceuticals (NASDAQ:TELO) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Telomir Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

61.3% of Puma Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Puma Biotechnology	$228.40M	1.79	$31.11M	$0.48	16.75

In the previous week, Puma Biotechnology's average media sentiment score of 0.81 beat Telomir Pharmaceuticals' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
Puma Biotechnology	Positive

Puma Biotechnology has a net margin of 10.69% compared to Telomir Pharmaceuticals' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Puma Biotechnology	10.69%	20.30%	12.05%

Summary

Puma Biotechnology beats Telomir Pharmaceuticals on 11 of the 12 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to SOPHiA GENETICS?

SOPHiA GENETICS (NASDAQ:SOPH) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, SOPHiA GENETICS had 8 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 8 mentions for SOPHiA GENETICS and 0 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.00 beat SOPHiA GENETICS's score of -0.16 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SOPHiA GENETICS	Neutral
Telomir Pharmaceuticals	Neutral

SOPHiA GENETICS has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

Telomir Pharmaceuticals has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. SOPHiA GENETICS's return on equity of -62.74% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

SOPHiA GENETICS presently has a consensus target price of $7.50, suggesting a potential upside of 43.40%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, research analysts plainly believe SOPHiA GENETICS is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$81.18M	5.40	-$79M	-$0.52	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

SOPHiA GENETICS beats Telomir Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Enanta Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Telomir Pharmaceuticals has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Enanta Pharmaceuticals	$65.32M	6.26	-$81.89M	-$2.59	N/A

Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 44.28%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for Enanta Pharmaceuticals and 0 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.00 equaled Enanta Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
Enanta Pharmaceuticals	Neutral

Telomir Pharmaceuticals has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Summary

Enanta Pharmaceuticals beats Telomir Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Greenwich LifeSciences has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

In the previous week, Greenwich LifeSciences' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Greenwich LifeSciences	Neutral
Telomir Pharmaceuticals	Neutral

4.2% of Greenwich LifeSciences shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals' return on equity of -201.23% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Greenwich LifeSciences presently has a consensus target price of $47.50, indicating a potential upside of 106.25%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Greenwich LifeSciences beats Telomir Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Telomir Pharmaceuticals has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	413.31	-$48.81M	-$0.63	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

In the previous week, Shattuck Labs had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 1 mentions for Shattuck Labs and 0 mentions for Telomir Pharmaceuticals. Shattuck Labs' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Shattuck Labs	Neutral
Telomir Pharmaceuticals	Neutral

Shattuck Labs' return on equity of -60.73% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

Shattuck Labs presently has a consensus target price of $11.00, indicating a potential upside of 104.08%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Shattuck Labs beats Telomir Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$88.03M	$2.96B	$6.45B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-4.31	18.43	24.66	23.99
Price / Sales	N/A	324.90	526.33	107.23
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	7.35	4.11	10.72	6.50
Net Income	-$10.41M	$64.45M	$3.56B	$336.88M
7 Day Performance	N/A	1.41%	0.94%	-0.16%
1 Month Performance	-3.10%	1.04%	0.36%	0.76%
1 Year Performance	-28.98%	23.88%	29.67%	28.49%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	0.4825 of 5 stars	$1.25 -2.3%	N/A	-26.0%	$88.03M	N/A	N/A	1
PBYI Puma Biotechnology	1.3526 of 5 stars	$7.13 -0.6%	N/A	+140.0%	$362.30M	$227.18M	14.83	200
SOPH SOPHiA GENETICS	2.2471 of 5 stars	$5.29 +7.3%	$7.50 +41.8%	+71.5%	$361.97M	$77.27M	N/A	520	High Trading Volume
ENTA Enanta Pharmaceuticals	1.4386 of 5 stars	$12.40 +2.7%	$20.29 +63.7%	+97.5%	$360.48M	$65.32M	N/A	160	News Coverage Analyst Forecast
GLSI Greenwich LifeSciences	1.2162 of 5 stars	$24.34 +1.9%	$47.50 +95.2%	+162.9%	$357.26M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. PBYI, SOPH, ENTA, GLSI, and STTK

How does Telomir Pharmaceuticals compare to Puma Biotechnology?

Summary

How does Telomir Pharmaceuticals compare to SOPHiA GENETICS?

Summary

How does Telomir Pharmaceuticals compare to Enanta Pharmaceuticals?

Summary

How does Telomir Pharmaceuticals compare to Greenwich LifeSciences?

Summary

How does Telomir Pharmaceuticals compare to Shattuck Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. PBYI, SOPH, ENTA, GLSI, and STTK

How does Telomir Pharmaceuticals compare to Puma Biotechnology?

Which has more volatility & risk, TELO or PBYI?

Do analysts rate TELO or PBYI?

Do insiders & institutionals have more ownership in TELO or PBYI?

Which has preferable earnings & valuation, TELO or PBYI?

Does the media favor TELO or PBYI?

Is TELO or PBYI more profitable?

Summary

How does Telomir Pharmaceuticals compare to SOPHiA GENETICS?

Does the media prefer SOPH or TELO?

Which has more risk and volatility, SOPH or TELO?

Is SOPH or TELO more profitable?

Do analysts rate SOPH or TELO?

Which has higher valuation & earnings, SOPH or TELO?

Do institutionals and insiders hold more shares of SOPH or TELO?

Summary

How does Telomir Pharmaceuticals compare to Enanta Pharmaceuticals?

Which has better valuation and earnings, TELO or ENTA?

Which has more volatility and risk, TELO or ENTA?

Do insiders and institutionals hold more shares of TELO or ENTA?

Do analysts rate TELO or ENTA?

Does the media refer more to TELO or ENTA?

Is TELO or ENTA more profitable?

Summary

How does Telomir Pharmaceuticals compare to Greenwich LifeSciences?

Which has preferable valuation and earnings, GLSI or TELO?

Which has more volatility and risk, GLSI or TELO?

Does the media prefer GLSI or TELO?

Do institutionals & insiders believe in GLSI or TELO?

Is GLSI or TELO more profitable?

Do analysts prefer GLSI or TELO?

Summary

How does Telomir Pharmaceuticals compare to Shattuck Labs?

Which has better earnings and valuation, STTK or TELO?

Does the media favor STTK or TELO?

Is STTK or TELO more profitable?

Do institutionals and insiders believe in STTK or TELO?

Which has more risk and volatility, STTK or TELO?

Do analysts rate STTK or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools